X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1448) 1448
Publication (245) 245
Book Review (30) 30
Book Chapter (6) 6
Conference Proceeding (2) 2
Magazine Article (1) 1
Streaming Video (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (1095) 1095
index medicus (943) 943
ctla-4 antigen - antagonists & inhibitors (746) 746
animals (623) 623
immunotherapy (607) 607
oncology (479) 479
programmed cell death 1 receptor - antagonists & inhibitors (457) 457
immunology (436) 436
cancer (419) 419
antibodies, monoclonal - therapeutic use (399) 399
mice (385) 385
ipilimumab (384) 384
melanoma (359) 359
female (344) 344
ctla-4 antigen - immunology (333) 333
ctla-4 (300) 300
male (292) 292
immunotherapy - methods (262) 262
b7-h1 antigen - antagonists & inhibitors (259) 259
ctla-4 antigen (248) 248
antineoplastic agents - therapeutic use (235) 235
lymphocytes (235) 235
melanoma - drug therapy (228) 228
t cells (212) 212
neoplasms - immunology (203) 203
metastatic melanoma (200) 200
ctla-4 protein (197) 197
lymphocytes t (196) 196
care and treatment (186) 186
t-lymphocytes - immunology (186) 186
ctla-4 blockade (183) 183
tumors (179) 179
article (176) 176
programmed cell death 1 receptor - immunology (176) 176
nivolumab (170) 170
melanoma - immunology (165) 165
pd-1 (164) 164
expression (162) 162
immune checkpoint (161) 161
treatment outcome (160) 160
antibodies, monoclonal - pharmacology (157) 157
abatacept (155) 155
mice, inbred c57bl (147) 147
middle aged (147) 147
antigens (146) 146
neoplasms - therapy (141) 141
antibodies, monoclonal - adverse effects (138) 138
regulatory t-cells (138) 138
research (133) 133
therapy (131) 131
antigens, cd (130) 130
neoplasms - drug therapy (129) 129
t-cells (128) 128
chemotherapy (123) 123
dendritic cells (122) 122
immunoconjugates (121) 121
aged (120) 120
immune system (120) 120
medicine, research & experimental (119) 119
molecular targeted therapy (119) 119
cytotoxicity (118) 118
metastasis (118) 118
health aspects (117) 117
adult (116) 116
activation (115) 115
clinical trials as topic (114) 114
t-lymphocytes, regulatory - immunology (111) 111
open-label (110) 110
antitumor immunity (109) 109
patients (109) 109
ctla-4 antigen - metabolism (108) 108
b7-h1 antigen - immunology (107) 107
clinical trials (107) 107
in-vivo (107) 107
antibodies, monoclonal - administration & dosage (106) 106
blockade (106) 106
antibodies (105) 105
analysis (104) 104
pd-1 blockade (102) 102
cell line, tumor (101) 101
melanoma - pathology (101) 101
antineoplastic agents - pharmacology (100) 100
apoptosis (97) 97
immune response (97) 97
melanoma - therapy (97) 97
antineoplastic combined chemotherapy protocols - therapeutic use (96) 96
cd8-positive t-lymphocytes - immunology (96) 96
pd-1 protein (96) 96
mice, inbred balb c (95) 95
survival (95) 95
t cell receptors (95) 95
monoclonal antibodies (94) 94
pembrolizumab (94) 94
chemical and pharmacologic phenomena (93) 93
skin neoplasms - drug therapy (90) 90
cell biology (89) 89
cancer therapies (88) 88
combined modality therapy (88) 88
disease models, animal (88) 88
safety (88) 88
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1403) 1403
French (17) 17
German (9) 9
Czech (6) 6
Japanese (5) 5
Danish (3) 3
Chinese (2) 2
Hungarian (2) 2
Hebrew (1) 1
Italian (1) 1
Polish (1) 1
Spanish (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


European Journal of Cancer, ISSN 0959-8049, 2015, Volume 54, pp. 139 - 148
Journal Article
Journal Article
Journal Article
Science, ISSN 0036-8075, 02/2018, Volume 359, Issue 6375, pp. 582 - 587
CD8(+) T cell-dependent killing of cancer cells requires efficient presentation of tumor antigens by human leukocyte antigen class I (HLA-I) molecules.... 
HIV-1 | METASTATIC MELANOMA | CTLA-4 BLOCKADE | THERAPY | PD-1 BLOCKADE | MULTIDISCIPLINARY SCIENCES | MUTATIONAL LANDSCAPE | RESISTANCE | IDENTIFICATION | HISTOCOMPATIBILITY ANTIGENS | MOLECULES | Immunotherapy - methods | Humans | Middle Aged | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Young Adult | Cancer Vaccines - therapeutic use | Antigen Presentation | Melanoma - genetics | Skin Neoplasms - mortality | Adult | Skin Neoplasms - immunology | Skin Neoplasms - therapy | Antigens, Neoplasm - immunology | Treatment Outcome | Histocompatibility Antigens Class I - genetics | Histocompatibility Antigens Class I - chemistry | Cancer Vaccines - immunology | Melanoma - immunology | Skin Neoplasms - genetics | Protein Conformation | Aged | CD8-Positive T-Lymphocytes - immunology | CTLA-4 Antigen - antagonists & inhibitors | Melanoma - therapy | Genetic Carrier Screening | Cohort Studies | Melanoma - mortality | Care and treatment | Histocompatibility antigens | Immunotherapy | HLA histocompatibility antigens | Genotype | Genetic aspects | Health aspects | Cancer | Peptides | CD8 antigen | Genes | Molecular dynamics | Cytotoxicity | Lymphocytes T | Vaccines | Homozygosity | Cancer vaccines | Cell recognition | Genotype & phenotype | Lymphocytes | Genotypes | Immune system | Antigen presentation | Antigens | Melanoma | Epitopes | Patients | Survival | Loci | Heterozygosity | White blood cells | Immune checkpoint | Cell death | Antigen (tumor-associated) | Loss of heterozygosity | Histocompatibility antigen HLA | Mutation | Recognition | Apoptosis
Journal Article
Nature, ISSN 0028-0836, 04/2015, Volume 520, Issue 7547, pp. 373 - 377
Journal Article
PLoS ONE, ISSN 1932-6203, 12/2013, Volume 8, Issue 12, p. e83139
CD28, CTLA-4 and PD-L1, the three identified ligands for CD80/86, are pivotal positive and negative costimulatory molecules that, among other functions,... 
IN-VITRO | ACTIVATION | HOMEOSTASIS | DENDRITIC CELLS | TOLERANCE | MULTIDISCIPLINARY SCIENCES | EXTRINSIC CONTROL | ANTI-CD28 ANTIBODY | UP-REGULATION | CUTTING EDGE | LYMPHOCYTES | B7-1 Antigen - antagonists & inhibitors | Cell Communication - immunology | B7-2 Antigen - genetics | B7-1 Antigen - genetics | Dendritic Cells - immunology | Humans | Molecular Targeted Therapy | T-Lymphocytes, Regulatory - immunology | T-Lymphocytes, Cytotoxic - drug effects | CD28 Antigens - genetics | Protein Binding - drug effects | CD28 Antigens - antagonists & inhibitors | T-Lymphocytes, Regulatory - cytology | Dendritic Cells - drug effects | B7-2 Antigen - immunology | T-Lymphocytes, Cytotoxic - immunology | Gene Expression | B7-2 Antigen - antagonists & inhibitors | B7-1 Antigen - immunology | Antibodies, Monoclonal - pharmacology | CTLA-4 Antigen - genetics | CD28 Antigens - immunology | CTLA-4 Antigen - immunology | B7-H1 Antigen - genetics | B7-H1 Antigen - immunology | Cell Movement - drug effects | T-Lymphocytes, Regulatory - drug effects | B7-H1 Antigen - antagonists & inhibitors | Lymphocyte Activation - drug effects | Cell Communication - drug effects | Dendritic Cells - cytology | CTLA-4 Antigen - antagonists & inhibitors | T-Lymphocytes, Cytotoxic - cytology | Viral antibodies | Antibodies | Antigens | B cells | T cells | Motility | Transplants & implants | Calcium | Blocking antibodies | Homeostasis | Effector cells | Reversing | Immunological synapses | Lymphocytes T | Kinases | CD28 antigen | T-cell receptor | CTLA-4 protein | Cell activation | Immunology | Lymphocytes | Dwell time | Cell cycle | Cytokines | Immunoregulation | CD80 antigen | T cell receptors | Costimulator | Microscopy | Antigen-presenting cells | PD-L1 protein | Ligands | Cell migration | Synapses | Apoptosis | Life Sciences | Human health and pathology
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 08/2017, Volume 23, Issue 15, pp. 4242 - 4250
Journal Article